DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Heart failure (HF) continues to be a major global health problem with a notable impact in terms of morbidity and mortality and so, in consequence, with a large unmet necessity for new therapies. The inhibition of sodium–glucose cotransporter 2 (SGLT2) causes glycosuria and natriuresis, leading to re...

Full description

Bibliographic Details
Main Author: Edgardo Kaplinsky
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-02-01
Series:Drugs in Context
Subjects:
dapagliflozin
sodium–glucose cotransporter 2 inhibitors
dapa-hf trial
define-hf trial
heart failure
Online Access:https://www.drugsincontext.com/dapa-hf-trial:-dapagliflozin-evolves-from-a-glucose-lowering-agent-to-a-therapy-for-heart-failure/

Internet

https://www.drugsincontext.com/dapa-hf-trial:-dapagliflozin-evolves-from-a-glucose-lowering-agent-to-a-therapy-for-heart-failure/

Similar Items